ALEC Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 137832 min ago

@ $6.07

Ausgestellt: 13 Feb 2024 @ 21:46

Rendite: -10.38%

Vorheriges Signal: Feb 13 - 15:30

Vorheriges Signal: Kaufen

Rendite: -2.10 %

Live Chart Being Loaded With Signals

Commentary (17 Mai 2024 @ 22:00):

Stats
Tagesvolumen	529 526
Durchschnittsvolumen	600 068
Marktkapitalisierung	524.33M
EPS	$0 ( 2024-05-09 )
Nächstes Ertragsdatum	( $-0.500 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	500 000	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Buy	98 533	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	98 533	Common Stock
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)

INSIDER POWER
-25.53
Last 100 transactions
Buy: 2 784 515 \| Sell: 4 159 752

Volumen Korrelation

Lang: 0.25 (neutral)

Kurz: 0.71 (moderate)

Signal:(73.417) Neutral

Alector Inc Korrelation

10 Am meisten positiv korreliert
AEHR	0.894
NEOG	0.893
VMAR	0.891
BROG	0.89
EHTH	0.889
LCID	0.885
EVOK	0.876
RVNC	0.876
NDRA	0.874
TXG	0.871

10 Am meisten negativ korreliert
BSCO	-0.847
ESTA	-0.83
NESR	-0.823
OXSQ	-0.82
PTMN	-0.817
LPCN	-0.811
SFBC	-0.81
KRUS	-0.808
IMPP	-0.805
AEAE	-0.802

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Alector Inc Korrelation - Währung/Rohstoff

-0.23
( neutral )

0.11
( neutral )

0.00
( neutral )

0.52
( weak )

Alector Inc Finanzdaten

Annual	2023
Umsatz:	$97.06M
Bruttogewinn:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2023
Umsatz:	$97.06M
Bruttogewinn:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2022
Umsatz:	$133.62M
Bruttogewinn:	$125.15M (93.66 %)
EPS:	$-1.620

FY	2021
Umsatz:	$207.09M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.467

Financial Reports:

No articles found.

Alector Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.